A high-throughput pathology approach for further insight into the role of RBM3 as a biomarker of prognosis and chemotherapy response in human cancer
Cancer incidence is increasing and it is the number one cause of death worldwide. Cancer is a highly heterogeneous disease and there is a great need for new early diagnostic, prognostic and treatment predictive biomarkers in order to improve patient outcomes. The RNA-binding motif protein 3, RBM3, is an emerging candidate biomarker of favourable prognosis and treatment response in several types of
